Capital Research Global Investors increased its holdings in Humana Inc. (NYSE:HUM) by 9.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,907,333 shares of the insurance provider’s stock after buying an additional 346,069 shares during the period. Capital Research Global Investors owned about 2.70% of Humana worth $940,182,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. AHL Partners LLP grew its stake in Humana by 10.8% in the 2nd quarter. AHL Partners LLP now owns 65,821 shares of the insurance provider’s stock valued at $15,838,000 after acquiring an additional 6,411 shares during the last quarter. Zurich Insurance Group Ltd FI increased its holdings in Humana by 30.3% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 26,566 shares of the insurance provider’s stock valued at $6,392,000 after acquiring an additional 6,178 shares in the last quarter. Miles Capital Inc. purchased a new position in Humana during the 2nd quarter valued at about $216,000. Sun Life Financial INC increased its holdings in Humana by 6,076.5% during the 2nd quarter. Sun Life Financial INC now owns 1,050 shares of the insurance provider’s stock valued at $253,000 after acquiring an additional 1,033 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its position in Humana by 190.5% during the second quarter. Tudor Investment Corp ET AL now owns 5,229 shares of the insurance provider’s stock worth $1,258,000 after acquiring an additional 3,429 shares during the last quarter. Institutional investors and hedge funds own 95.12% of the company’s stock.

In related news, CEO Bruce D. Broussard sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the transaction, the chief executive officer now owns 80,086 shares of the company’s stock, valued at $20,172,061.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider William Kevin Fleming sold 3,071 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the transaction, the insider now directly owns 7,681 shares in the company, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,595 shares of company stock valued at $14,133,706. 0.80% of the stock is owned by corporate insiders.

WARNING: “Capital Research Global Investors Grows Stake in Humana Inc. (HUM)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/capital-research-global-investors-grows-stake-in-humana-inc-hum/1603413.html.

A number of brokerages have recently weighed in on HUM. UBS AG reissued a “neutral” rating and set a $237.00 price objective (up from $205.00) on shares of Humana in a research note on Wednesday, June 28th. BidaskClub upgraded Humana from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Morgan Stanley upped their target price on Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research note on Thursday, August 17th. Zacks Investment Research lowered Humana from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 target price (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $246.60.

Humana Inc. (NYSE:HUM) traded up 0.50% during midday trading on Monday, reaching $244.85. The company’s stock had a trading volume of 323,410 shares. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $259.76. The firm has a market capitalization of $35.38 billion, a price-to-earnings ratio of 20.14 and a beta of 0.86. The stock’s 50-day moving average price is $250.95 and its 200-day moving average price is $232.23.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the previous year, the company posted $2.30 EPS. Analysts predict that Humana Inc. will post $11.55 EPS for the current year.

The company also recently disclosed a dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio is 13.06%.

Humana Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.